{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mooney B"],"funding":["Stand Up To Cancer","Michael Smith Health Research BC","BC Cancer Foundation","St. Baldrick's Foundation","NCI NIH HHS","National Institutes of Health","Cancer Prevention and Research Institute of Texas","Canadian Institutes of Health Research"],"pagination":["1022-1037"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10905525"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(5)"],"pubmed_abstract":["Purpose
Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.Experimental design
This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient u"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma."],"pmcid":["PMC10905525"],"funding_grant_id":["UO1CA263981","SU2C-AACR-DT1113","R35 CA220500","1U54CA232568-01","U01 CA263981","R35CA220500","RP160716","T32 CA009140","CA009140","U54 CA232568","415377","18569","RT-2023-3194"],"pubmed_authors":["Shraim R","Lizardo MM","Maris JM","Sorensen PH","Mooney B","Dimitrov DS","Spencer Miko SE","El-Naggar AM","Houghton PJ","Zhang HF","Delaidelli A","Li W","Kurmasheva RT","Hughes CS","Diskin SJ","Negri GL","Shyp T","Weiner AK","Morin GB","Li A","Radaoui AB","Rouleau M"],"additional_accession":[]},"is_claimable":false,"name":"Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.","description":"Purpose
Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.Experimental design
This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient u","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-08T06:07:57.377Z","creation":"2025-05-29T20:46:31.097Z"},"accession":"S-EPMC10905525","cross_references":{"pubmed":["37812652"],"doi":["10.1158/1078-0432.CCR-23-2187"]}}